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Summary
 
Although lymphoid dendritic cells (DC) are thought to play an essential role in T cell activa-
tion, the initial physical interaction between antigen-bearing DC and antigen-specific T cells
has never been directly observed in vivo under conditions where the specificity of the respond-
ing T cells for the relevant antigen could be unambiguously assessed. We used confocal micros-
copy to track the in vivo location of fluorescent dye-labeled DC and naive TCR transgenic
CD4
 
 
 
 T cells specific for an OVA peptide–I-A
 
d
 
 complex after adoptive transfer into syngeneic
recipients. DC that were not exposed to the OVA peptide, homed to the paracortical regions
of the lymph nodes but did not interact with the OVA peptide-specific T cells. In contrast, the
OVA peptide-specific T cells formed large clusters around paracortical DC that were pulsed in
vitro with the OVA peptide before injection. Interactions were also observed between para-
cortical DC of the recipient and OVA peptide-specific T cells after administration of intact
OVA. Injection of OVA peptide-pulsed DC caused the specific T cells to produce IL-2 in
vivo, proliferate, and differentiate into effector cells capable of causing a delayed-type hyper-
sensitivity reaction. Surprisingly, by 48 h after injection, OVA peptide-pulsed, but not un-
pulsed DC disappeared from the lymph nodes of mice that contained the transferred TCR
transgenic population. These results demonstrate that antigen-bearing DC directly interact
with naive antigen-specific T cells within the T cell–rich regions of lymph nodes. This interac-
tion results in T cell activation and disappearance of the DC.
 
I
 
n vitro and in vivo studies have shown that bone mar-
row–derived dendritic cells (DC)
 
1
 
 are the most effective
APCs at activating naive CD4
 
 
 
 T cells (1). This efficiency
is thought to be related to the fact that DC express high
levels of class II MHC, adhesion, and costimulatory mole-
cules, which play essential roles in T cell activation (1). In
addition, DC are the most abundant class II MHC–express-
ing APC in the T cell–rich areas of secondary lymphoid tis-
sues, and are thus well-positioned to interact with naive T
cells.
Although in vitro experiments strongly indicate that DC
are the initiating APC for T cell responses in vivo, sugges-
tive evidence supporting this idea has only recently been
reported (2, 3). Proliferating T cells have been observed in
contact with the DC of the T cell areas of lymphoid tissue
after injection of superantigens (2) or allogeneic cells (3).
However, because methodologies did not exist for in situ
detection of the few T cells specific for any given peptide–
MHC complex in unimmunized individuals, it has not been
possible to definitively demonstrate interactions between
naive, peptide antigen-specific T cells and antigen-bearing
dendritic cells in vivo. To overcome this difficulty, we pre-
viously developed (5) an adoptive transfer system in which
a small but detectable number of naive DO11.10 TCR
transgenic CD4
 
 
 
 cells are injected intravenously into nor-
mal syngeneic BALB/c recipients. The majority of the
CD4
 
 
 
 T cells in the DO11.10 TCR transgenic mice (6)
are specific for a chicken OVA peptide 323-339/I-A
 
d
 
 class
II MHC complex (7), and can be detected with the KJ1-26
mAb (8), which is uniquely specific for the DO11.10 clo-
notypic TCR. We used this system here, to characterize
interactions between peptide–MHC-bearing DC and naive
antigen-specific CD4
 
 
 
 T cells during in vivo immune re-
sponses.
 
Materials and Methods
 
Animals.
 
DO11.10 BALB/c mice were produced by back-
crossing the original DO11.10 TCR-transgenic mice (kindly
provided by Dr. Dennis Loh) with BALB/c (H-2
 
d
 
) mice (pur-
 
1
 
Abbreviations used in this paper: 
 
CMFDA, 5-chloromethylfluorescein diace-
tate; CMTMR, 5-(and -6)-(((4-chloromethyl) benzoyl) amino) tetremeth-
ylrhodamine; DC, dendritic cell; DTH, delayed-type hypersensitivity; SA,
streptavidin.
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chased from the National Cancer Institute, Frederick, MD) for
 
 
 
10 generations. DO11.10 BALB/c SCID mice were produced
by back-crossing DO11.10 BALB/c mice with BALB/c SCID mice
(purchased from the National Cancer Institute, Frederick, MD)
for two generations and selecting for offspring that contained
DO11.10 T cells and no other lymphocytes (as assessed by flow
cytometric analysis of blood cells stained with KJ1-26 and anti-
B220 mAbs). All DO11.10 BALB/c and BALB/c SCID mice
were bred and housed under specific pathogen-free conditions.
6–8-wk-old, sex-matched mice were used for all experiments.
Mice were cared for in accordance with University of Minnesota
and NIH guidelines.
 
Purification and Labeling of CD4
 
 
 
 T Cells.
 
Lymph node cells from
DO11.10 or BALB/c donor mice were passed over an anti-CD8
and anti-immunoglobulin column (Biotex, Edmonton, Alberta) to
enrich for CD4
 
 
 
 T cells. Lymph node cells from DO11.10 SCID
mice were passed over a G10 column to eliminate macrophages.
The T cells were labeled with the green fluorescent dye, 5-chlo-
romethylfluorescein diacetate (CMFDA), according to the manu-
facturer’s protocol (Molecular Probes, Eugene, OR) and 2.5 
 
 
 
 10
 
6
 
labeled cells were injected intravenously into syngeneic BALB/c
mice.
 
Isolation and Labeling of DC.
 
Splenic DC were enriched ac-
cording to the method of Steinman and coworkers (9). In brief,
spleen fragments were subjected to mild collagenase digestion at
37
 
 
 
C for 60 min to release DC. Low density cells were selected
by centrifugation on a 35% bovine serum albumin gradient
(Sigma Chem. Co., St. Louis, MO), cultured in plastic dishes for
1–2 h after which the nonadherent cells were washed away. The
adherent cells were cultured overnight with 100 
 
 
 
g/ml of OVA
peptide 323-339 (referred to hereafter as OVA peptide) or me-
dium. The DC, which detached from the plates during the incu-
bation period, were collected and labeled with the red fluorescent
dye, 5-(and -6)-(((4-chloromethyl) benzoyl) amino) tetramethyl-
rhodamine (CMTMR), according to the manufacturer’s protocol
(Molecular Probes). DC were injected subcutaneously (0.5 
 
 
 
 10
 
6
 
in 30–50 
 
 
 
l of PBS) into the hind foot pads of recipient mice the
day after the DO11.10 T cell transfer. Splenic DC were used in-
stead of the DC that can be obtained from cytokine-stimulated
bone marrow cultures, to minimize potential presentation of FCS
serum proteins that could lead to background detection of FCS-
specific T cells (10).
 
Flow Cytometry.
 
DC purity was confirmed by flow cytometry
as described by Levin et al. (11). In brief, purified DC (10
 
5
 
) were
incubated with FITC-labeled anti-FcR mAb 2.4G2 (PharMin-
gen, San Diego, CA), FITC-labeled anti-B220 mAb RA3-6B2
(PharMingen), biotin-labeled anti-class II MHC mAb M5/114, and
PE-labeled streptavidin (SA) (Caltag, South San Francisco, CA)
sequentially on ice for 15–20 min, with washes between steps.
10,000 events were collected on a Becton Dickinson FACScan
 

 
(Mountain View, CA) flow cytometer and analyzed using Lysis II
software. DC were identified as class II MHC
 
 
 
, Fc receptor
 
 
 
,
B220
 
 
 
 cells; and 
 
 
 
85% of the cells were DC by these criteria. To
obtain the percentage of CD4
 
 
 
, KJ1-26
 
 
 
 cells, popliteal lymph
node cells (10
 
6
 
) were stained with PE-labeled anti-CD4 mAb
H129.19 (PharMingen) and biotin-labeled KJ1-26 mAb followed
by SA-FITC (Caltag). After washing, 10,000 events were col-
lected and analyzed. For intracellular IL-2 staining, popliteal lymph
node cells (1-5 
 
 
 
 10
 
6
 
) were stained with CyChrome-labeled
anti-CD4 mAb RM4-5 (PharMingen) and biotin-labeled KJ1-26
mAbs followed by SA-FITC. Cells were then fixed in 2% formal-
dehyde, and permeabilized with 0.5% saponin, as previously de-
scribed (12, 13). A PE-labeled anti–IL-2 mAb S4B6 (PharMin-
gen) or isotype control mAb R35-95 (PharMingen) was then
added to detect cytosolic IL-2. After washing, 1,000–3,000 CD4
 
 
 
,
KJ1-26
 
 
 
 or CD4
 
 
 
, KJ1-26
 
 
 
 events were collected and analyzed.
 
Immunofluorescent Microscopy.
 
Draining popliteal lymph nodes
were harvested from sacrificed mice at various times after the DC
injections. The lymph nodes were frozen in liquid nitrogen. Cry-
ostat-cut tissue sections (24 
 
 
 
m) were fixed in 4% paraformalde-
hyde and washed in PBS. In some experiments, lymph node sec-
tions (4 
 
 
 
m) were fixed in acetone, blocked with anti-FcR mAb
2.4G2 and stained sequentially with biotin-labeled N418 mAb
(anti-CD11c), biotin-labeled goat anti–hamster IgG (Caltag), fol-
lowed by Cy 3-labeled SA. Confocal microscopy and image anal-
yses were performed as previously described by Brelje et al. (14).
In brief, sections were analyzed using a confocal microscope
equipped with a krypton/argon laser (MRC-1000; Bio-Rad Life
Science Group, Hercules, CA). Separate green and red images
were collected for each section analyzed. Final image processing
was performed using the Confocal Assistant program (Minneapo-
lis, MN) and Adobe Photoshop (Mountain View, CA). The area
(mm
 
2
 
) of lymph node scanned was measured using MetaMorph
software (West Chester, PA). Adjacent tissue sections (4 
 
 
 
m) were
stained with biotin-labeled anti-CD4 mAb RM4-5 (PharMin-
gen) and SA-FITC (Caltag) or biotin-labeled anti-B220 mAb
RA3-6B2 (PharMingen) and SA-tetramethylrhodamine (Molec-
ular Probes) to identify the paracortical (T cell–rich) and follicular
(B cell–rich) regions of the lymph nodes by conventional immu-
nofluorescent microscopy.
 
Injections.
 
In some experiments, mice were injected subcuta-
neously in the hind foot pad with a chemical conjugate of OVA
and hen egg lysozyme, which was designed for use in T cell/B
cell collaboration experiments. This conjugate, and native OVA
stimulate DO11.10 T cells identically in vivo (data not shown). 
 
Delayed-type Hypersensitivity Response.
 
7 d after the initial DC
injections, mice were rechallenged with an intradermal injection
of soluble OVA (10 
 
 
 
g) in the ears. Ear thickness was measured
at the time of injection (baseline) and 24 h later by an individual
who was unaware of the experimental design. The degree of re-
sponse was calculated as the difference between the two measure-
ments.
 
Results
 
In Vivo Analysis of Interactions between Antigen-pulsed DC and
Antigen-specific CD4
 
 
 
 T Cells.
 
Using immunohistochemi-
cal detection with the KJ1-26 mAb, we previously showed
that DO11.10 T cells were present in the T cell–rich para-
cortical regions of all lymph nodes within 24 h of intrave-
nous injection (5). Similarly, intravenously injected, CM-
FDA-labeled DO11.10 T cells were found in the paracortical
regions of the lymph nodes (Fig. 1) 24 h after injection, in-
dicating that the dye labeling process did not affect their
trafficking ability. In the absence of antigen, the CMFDA-
labeled DO11.10 T cells could be detected via their green
fluorescence in the paracortical regions for at least 72 h
(data not shown). CMTMR-labeled, unpulsed DC were
first detected in the draining lymph nodes 8 h after subcu-
taneous injection, accumulated to a maximal level by 24 h,
and declined slightly by 48 h (Figs. 2 
 
B
 
 and 3 
 
A
 
). By 24 h,
the unpulsed DC were found almost exclusively in the
paracortical regions of the lymph nodes (Fig. 1 
 
B
 
). Despite
the paracortical colocalization of the labeled T cells and un- 
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pulsed DC, few if any interactions between the cells were
observed throughout the 48-h observation period (Figs. 1
 
B
 
, 2 
 
B
 
, and 3 
 
B
 
).
A very different pattern was observed after injection of
OVA peptide-pulsed DC. The rate of entry of OVA pep-
tide-pulsed DC into the lymph nodes over the first 24 h
was similar to that observed for unpulsed DC (Figs. 2 
 
A
 
and 3 
 
A
 
). However, at each time point, clusters of DO11.10
T cells (
 
 
 
2 cells) were observed surrounding the OVA
peptide-pulsed DC (Figs. 1 
 
A
 
, 2 
 
A
 
, and 3 
 
B
 
). At 24 h, the
time of maximal DC accumulation, 
 
 
 
70% of the OVA
peptide-pulsed DC were surrounded by many DO11.10 T
cells. In addition, at this magnification, areas of yellow
color appeared in the clusters reflecting overlap between
the red and green images and close contact between the T
cells and DC. The specificity of cluster formation was indi-
cated by the finding that clusters were not observed in mice
that received CMFDA-labeled polyclonal BALB/c CD4
 
 
 
T cells and were injected 24 h previously with CMTMR-
labeled OVA peptide-pulsed DC (Fig. 3 
 
B
 
).
Although the high degree of coincidence between OVA
peptide-pulsed DC and DO11.10 T cell clusters at 24 h
made it likely that the clusters represented bona fide inter-
actions between the two cell types, the 
 
 
 
5-
 
 
 
m-thickness
of the optical sections made it formally possible that the
dendritic cells were not centrally located within the clus-
ters, but rather were situated immediately above or below
the clusters. Serial optical sectioning through individual
cluster-associated, OVA peptide-pulsed dendritic cells was
performed at high power (optical section thickness 
 
 
 
 0.6
Figure 2. In vivo clustering of
OVA peptide–MHC-bearing
DC and DO11.10 T cells.
DO11.10 T cells (green) and DC
(red) were purified, dye-labeled
and injected into recipient mice
as described in Materials and
Methods. Draining popliteal
lymph nodes were harvested 4, 8,
24, and 48 h after DC injections.
Tissue was processed and ana-
lyzed by confocal microscopy as
described in Materials and Meth-
ods. The optical thickness of
each image is 4.5–5  m. Images
were taken from paracortical re-
gions of lymph nodes of mice in-
jected with (A) OVA peptide-
pulsed DC or (B) unpulsed DC.
Bar, 100  m.
 
Figure 1.
 
Visualization of OVA peptide–MHC-bearing DC and CD4
 
 
 
T cell interactions in situ. CMFDA-labeled DO11.10 T cells (
 
green
 
) and
CMTMR-labeled DC (
 
red
 
) were purified, dye-labeled and injected into
recipient mice as described in Materials and Methods. Draining popliteal
lymph nodes were harvested 24 h after DC injections. Tissue was processed
and analyzed by confocal microscopy as described in Materials and Methods.
 
The full-width half peak resolution of the sampling volume was 4.5–5.0 
 
 
 
m;
in other words, the optical thickness of each image is 4.5–5 
 
 
 
m. Images
were taken from lymph nodes of mice injected with (
 
A
 
) OVA peptide-
pulsed DC or (
 
B
 
) unpulsed DC. Follicular regions, defined on adjacent
 
sections as areas rich in B220
 
 
 
 cells, are indicated (
 
*
 
). Bar, 150 
 
 
 
m. 
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Figure 3. Kinetics of DC ap-
pearance and cluster formation in
draining lymph nodes. CMFDA-
labeled DO11.10 (circles) or poly-
clonal BALB/c (triangles) CD4 
T cells were injected intrave-
nously into BALB/c recipient
mice the day before CMTMR-
labeled OVA peptide-pulsed
(closed symbols) or unpulsed (open
symbols) DC were injected sub-
cutaneously into the hind foot
pads. Draining popliteal lymph
nodes were harvested at the indi-
cated times after DC injection
and analyzed with two-color
confocal immunofluorescent mi-
croscopy as described in Materi-
als and Methods. One image was
collected per 24- m section to
ensure that individual fluorescent
cells were only counted once. An interaction was defined as two or more green T cells overlapping a red DC such that a yellow area was produced. The
number of DC (A) and DC engaged in T cell interactions (B) were quantified per unit area (mm2) of lymph node. The results represent the mean values
  SD of 2–3 mice/group (except for the results from the polyclonal BALB/c T cell group, which came from a single animal) derived from a single ex-
periment. Similar values were obtained in two other independent experiments.
Figure 4. Detailed analysis of
a DC–T cell cluster. A series of
optical sections was taken at 1- m
intervals through a dendritic cell
that appeared to be surrounded
by T cells 24 h after the injection
of OVA peptide-pulsed DC. At
this magnification, the optical
thickness of each image is  0.6
 m. Bar, 10  m. 
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m) to assess this possibility. As shown in Fig. 4, interac-
tions between the dendritic cell and several DO11.10 T
cells were observed in each serial plane of focus through
the dendritic cell body. Similar results were observed for all
clusters examined in this way (n 
 
 
 
 5). These results dem-
onstrate that OVA peptide-pulsed dendritic cells are cen-
trally located within the clusters at the 24-h time point, and
are simultaneously interacting with many DO11.10 T cells.
48 h after injection, essentially all of the OVA peptide-
pulsed DC were surrounded by DO11.10 T cells (Fig. 2
 
A
 
). However, the number of DO11.10 T cells present in
the clusters was reduced and the number of OVA peptide-
pulsed DC present was lower than was observed in recipi-
ents of unpulsed DC at this time (Fig. 3 
 
A
 
). The disappear-
ance of OVA peptide-pulsed DC at 48 h appeared to be a
function of the presence of DO11.10 T cells and the ability
to induce cluster formation, because OVA peptide-pulsed
DC persisted to the same degree as unpulsed DC when in-
jected into mice that previously received CMFDA-labeled
polyclonal BALB/c T cells (Fig. 3 
 
A
 
).
Approximately 75% of the CD4  cells purified from the
DO11.10 mice express the DO11.10 TCR-  and TCR- 
chains (6, 15). Because of incomplete allelic exclusion, the
remaining 25% express the DO11.10 TCR-  chain with
an endogenous TCR-  chain, and are specific for antigens
other than OVA (15). DO11.10 mice were backcrossed
with SCID mice, which produce endogenous TCR-  chains
only at very low levels, to exclude the possibility that en-
dogenous TCR-  chain–expressing T cells were interact-
ing with the DC. Flow cytometric analysis of lymph node
cells from DO11.10 SCID mice confirmed that essentially
all of the CD4  T cells in these mice also stained with the
KJ1-26 mAb (data not shown). CMFDA-labeled DO11.10
SCID T cells clustered around 36   3% of the CMTMR-
labeled, OVA peptide-pulsed DC and 0   0% of the
CMTMR-labeled unpulsed DC, 24 h after DC injection.
Figure 5. Flow cytometric de-
tection of intracellular IL-2.
DO11.10 recipient mice were
injected subcutaneously in the
hind foot pads with OVA pep-
tide-pulsed or unpulsed DC.
Draining popliteal lymph node
cells were harvested 8 and 24 h
later, and stained for intracellular
IL-2 protein as described in Ma-
terials and Methods. A gate was
drawn on the CD4 , KJ1-26 
(R2), or CD4 , KJ1-26   (R3)
cells from each group based on a
dot plot of the type shown in A.
The amount of IL-2 staining is
expressed as a histogram for
CD4 , KJ1-26  ( B) or CD4 ,
KJ1-26  (C) cells from mice in-
jected 24 h previously with
OVA peptide-pulsed (thick line)
or unpulsed (dashed line) DC.
The mean percentage of IL-2 
cells (  range) in the M1 gate
(see B and C) from two individ-
ual mice/group is shown in D.
Similar results were obtained in
an independent experiment.2138 Visualization of In Vivo Antigen Presentation
In this same experiment, we found that CMFDA-labeled
DO11.10 SCID T cells also failed (0   0%) to cluster
around CMTMR-labeled unpulsed DC in mice that also
received unlabeled OVA peptide-pulsed DC at the same
time. Together these results demonstrated that CD4  T
cells expressing the DO11.10 TCR were responsible for
cluster formation and that cluster formation required that
the OVA peptide-pulsed DC present the relevant peptide–
MHC complex. Furthermore, because the DO11.10 SCID
T cells uniformly expressed a naive surface phenotype
(CD45RBhigh, L-selectinhigh) at the time of adoptive trans-
fer (15, data not shown), these results also demonstrate that
naive antigen-specific T cells interact with peptide–MHC-
bearing DC in vivo.
The physical interactions between the DO11.10 T cells
and OVA peptide-pulsed DC correlated with activation of
the T cells. Intracellular staining with anti–IL-2 antibody
showed that a significant fraction of the DO11.10 T cells
present in recipients injected with OVA peptide-pulsed
DC at the time of maximal cluster formation (24 h) were
producing the growth factor IL-2 (Fig. 5, B and D). The
specificity of this response was demonstrated by the finding
that IL-2 production was not detected in DO11.10 cells
from mice injected with unpulsed DC (Fig. 5, B and D) or
in the CD4 , KJ1-26  T cells (recipient T cells) present
in mice injected with OVA peptide-pulsed DC (Fig. 5, C
and D).
48 h after injection of OVA peptide-pulsed DC about
one-third of the CMFDA-labeled DO11.10 T cells were
dull green (Fig. 2 A), perhaps because of dilution of the dye
as a consequence of cell division. By 72 h, the number of
DO11.10 T cells in mice injected with OVA peptide-
pulsed DC, but not unpulsed DC increased dramatically in
the draining lymph nodes, and this increase continued to
a peak at 96 h (Fig. 6). Normal mice or recipients of
DO11.10 T cells that had been injected with DC 7 d ear-
lier were rechallenged with soluble OVA subcutaneously in
the ear to determine if T cells capable of causing an OVA-
specific DTH response had been induced. DO11.10 recipi-
ent mice that had been previously injected with OVA pep-
tide-pulsed DC, but not unpulsed DC mounted a strong
DTH reaction that surpassed that of similarly primed
BALB/c mice that did not receive DO11.10 T cells (Fig.
7), suggesting that the DO11.10 T cells participated in the
delayed-type hypersensitivity (DTH) reaction in the former
situation.
In Vivo Analysis of Interactions Between Resident Lymph
Node DC and Antigen-specific CD4  T Cells after Injection of
Soluble Antigen. Finally, we determined whether the un-
labeled endogenous DC of the recipient could form clus-
ters with CMFDA-labeled DO11.10 T cells in vivo after
injection of a soluble form of intact OVA to ensure that
cluster formation was a property of DC that had not been
through the purification and labeling process. As shown in
Fig. 8, in the absence of OVA, CMFDA-labeled DO11.10
SCID T cells were not clustered and were rarely found in-
teracting with endogenous paracortical DC (Fig. 8 B). In
contrast, 24 h after injection of OVA, CMFDA-labeled
DO11.10 T cells formed small clusters, many of which
showed evidence (yellow) of interactions with endogenous
paracortical DC of the recipient (Fig. 8 A).
Discussion
The ability to physically monitor the anatomic location
of naive antigen-specific T cells and DC allowed us to
reach several conclusions about antigen presentation in vivo.
Because T cell/DC clusters were only observed when a
high frequency of OVA peptide-specific T cells and OVA
peptide–MHC-bearing DC were present at the same time
is strong evidence that the clusters represent antigen pre-
sentation events. This conclusion is further supported by
the findings that cluster formation coincided with IL-2
production by the antigen-specific T cells, and was fol-
lowed by proliferation and differentiation of the T cells into
DTH effector cells. Our results are consistent with those of
others who showed that clusters of proliferating T cells are
found in proximity to T cell zone DC after injection of su-
perantigens (2) or allogeneic cells (3). The capacity of indi-
vidual OVA peptide-pulsed DC to simultaneously interact
with many antigen-specific T cells in vivo is reminiscent of
the in vitro studies of Steinman and coworkers (16–19),
and provides a possible explanation for the ability of small
numbers of tumor peptide-pulsed DC to induce cancer im-
Figure 6. Kinetics of clonal expansion induced by injection of OVA
peptide-pulsed or unpulsed DC. BALB/c recipients of DO11.10 T cells
were injected subcutaneously in the hind foot pad with 0.5   106 OVA
peptide-pulsed DC (closed circles), 0.5   106 unpulsed DC (open circles), or
nothing (open squares). The draining popliteal lymph nodes were harvested
at various time points after injection. Flow cytometric analysis was per-
formed on 10,000 lymph node cells from each group after staining to ob-
tain the percentage of CD4 , KJ1-26  cells present at each time point.
The total number of CD4 , KJ1-26  cells was calculated by multiplying
the percentage of CD4 , KJ1-26  cells by the total number of lymph
node cells obtained from a viable cell count. The results represent the
mean values   range of two mice from a single experiment. Similar val-
ues were obtained from three other independent experiments.2139 Ingulli et al.
munity (20, 21). It should also be noted that DO11.10 T
cells formed clusters around endogenous DC following sol-
uble OVA injection indicating that indeed DC play an im-
portant role in antigen presentation in vivo. In this situa-
tion, however, DC–T cell clusters are smaller probably
because all of the DC have access to antigen and are thus in
competition with each other for antigen presentation to the
DO11.10 T cells.
The finding that very few DO11.10 T cells were found
in proximity to unpulsed DC despite colocalization to the
lymph node paracortex indicates that interactions between
antigen-specific CD4  T cells and DC in the absence of the
relevant antigen are very transient. It is possible that these
transient interactions are stabilized if the DC display the ap-
propriate peptide–MHC complexes and activate the inter-
acting T cells to upregulate the activity of their adhesion
molecules (22). The subsequent stable binding between an-
tigen-specific T cells and antigen-presenting DC would al-
low sustained TCR signaling, which has been shown to be
required for T cell commitment to lymphokine production
(23). An alternative possibility is that naive T cells are first
activated by an APC from the recipient before binding to
the OVA peptide-pulsed, labeled DC. This is unlikely be-
cause it would require transfer of OVA peptide from the
labeled DC to recipient APCs. This does not appear to be
the case because injection of OVA peptide-pulsed, unla-
beled DC together with unpulsed, labeled DC into recipi-
ents containing labeled DO11.10 T cells did not result in
cluster formation between the labeled populations as would
be expected if peptide transfer occurred.
It was surprising to find that OVA peptide-pulsed,
CMTMR-labeled DC rapidly disappeared from the lymph
nodes after the time of maximal interaction with DO11.10
T cells. It is possible that activation caused the labeled DC
to metabolize the dye and become undetectable. CD40 sig-
naling has been shown to stimulate cytokine production
and costimulatory molecule expression in DC, and the ac-
tivated DO11.10 T cells present in the clusters would be
expected to express CD40 ligand (24). However, if dye
metabolism due to DC activation was the only explanation,
then many DO11.10 T cell clusters lacking a labeled DC
should have been observed. This was not the case; many
fewer clusters were present at 48 h but most contained a la-
beled DC. Thus, a more likely explanation is that the DC
physically disappear because they migrate out of the lymph
node or are killed by the responding T cells. CD4  T cell
killing of the cognate APC has been described in several
cases (25, 26). In addition, a recent study by De Smedt et al.
Figure 7. DTH response. DO11.10 recipient mice were injected sub-
cutaneously in the hind foot pad with 0.5   106 OVA peptide-pulsed or
unpulsed DC. In addition, normal BALB/c mice were injected with 0.5  
106 OVA peptide-pulsed DC. 7 d after the initial injection, all mice were
rechallenged with an intradermal injection of soluble intact OVA (10  g)
in the ears. The results represent the mean ear swelling values   SD of
2–4 ears/group derived from a single experiment. Similar values were ob-
tained from three other independent experiments.
Figure 8. Endogenous DC cluster DO11.10 T cells in the presence of
antigen. DO11.10 SCID T cells were purified, CMFDA-labeled (green), and
injected into recipient mice as described in Materials and Methods. The
next day recipient mice were injected subcutaneously with 45  g of
OVA–hen egg lysozyme conjugate (A) or nothing (B). 24 h later, drain-
ing popliteal lymph nodes were harvested, sectioned, fixed in acetone,
and stained sequentially with biotin-labeled DC-specific mAb N418,
biotin-labeled goat anti–hamster IgG and Cy 3–labeled SA to detect en-
dogenous paracortical DC (red). Tissue was analyzed by confocal micros-
copy as described in Materials and Methods. The optical thickness of each
image is 2–3  m. Images shown were from paracortical regions of the
lymph nodes. Bar, 100  m.2140 Visualization of In Vivo Antigen Presentation
(27) showed that LPS also induces the activation and then
disappearance of DC in the spleen. Therefore, DC activa-
tion by inflammatory cytokines or cognate interactions
with antigen-specific T cells may eventually lead to elimi-
nation of the DC, allowing any interacting T cells to disen-
gage. By escaping from antigen-presenting DC, activated
T cells would be free to proliferate, interact with other
APCs such as antigen-specific B cells within the follicles,
and eventually to migrate out of the lymph node to non-
lymphoid sites of inflammation. Transient elimination of
antigen-presenting DC would also provide a mechanism
for terminating T cell responses, that could do damage if al-
lowed to go on unchecked.
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